MicroRNAs (miRs) have been proposed as minimally invasive prognostic markers for various types of cancer, including liver cancer, which is one of the most common cancers worldwide. In the present study, the expression of miR-34a in human liver cancer tissues and cell lines was evaluated and the effects of miR-34a on cell proliferation, invasion and glycolysis in hepatocellular carcinoma (HCC) cells were determined. The results indicated that miR-34a was downregulated in human liver cancer tissues. Overexpression of miR-34a significantly inhibited liver cancer cell proliferation and clone formation. In terms of the underlying mechanism, miR-34a was indicated to negatively regulate the expression of lactate dehydrogenase A (LDHA), which consequently inhibited LDHA-dependent glucose uptake in the cancer cells, as well as cell proliferation and invasion. Collectively, these data suggest that miR-34a functions as a negative regulator of glucose metabolism and may serve as a novel marker for liver cancer prognosis.
MAT catalyzes the only reaction that produces the major methyl donor in mammals. Low‐dose MTX is a commonly used DMARD. We tested the hypothesis that MTX inhibits MAT in vitro and in vivo. HepG2 cells were cultured under folate restriction or low‐dose MTX with and without folate or methionine supplementation. Mice received MTX regimens that reflected low‐dose clinical use in humans. We found that methionine or folate supplementation greatly improved SAM in folate‐depleted cells but not in cells preexposed to MTX. MTX but not folate depletion suppressed MAT genes, proteins and activity. Low‐dose MTX inhibited MAT1A and MAT2A genes, MATI/II/III proteins and MAT enzyme activities in mouse tissues. Concurrent folinate supplementation with MTX ameliorated MAT2A reduction and restored SAM in cells. However, posttreatment folinate rescue failed to restore MAT reduction or SAM level in cells preexposed to MTX. We provide both in vitro and in vivo evidence that lowdose MTX inhibits MAT genes, proteins, and enzyme activity independent of folate depletion. Because polyglutamated MTX stays in the hepatocytes, if MTX inhibits MAT in the liver, the efficacy of clinical folinate rescue with respect to maintaining hepatic SAM would be limited. The study raise concerns on perturbed methylation reactions in humans on low‐dose MTX. Well‐designed trials for optimizing SAM and methylation status in patients taking MTX are warrantedGrant Funding Source: National Science Council
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.